Loading...
ATRI logo

Atrion CorporationInforme acción NasdaqGS:ATRI

Capitalización bursátil US$809.4m
Precio de las acciones
n/a
US$225.18
n/adescuento intrínseco
1Y-3.1%
7D0.1%
1D
Valor de la cartera
​
Ver

Atrion Corporation

Informe acción NasdaqGS:ATRI

Capitalización de mercado: US$809.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Atrion (ATRI) Resumen de Acciones

Atrion Corporation, junto con sus filiales, desarrolla, fabrica y vende productos para aplicaciones de administración de fluidos, cardiovasculares y oftálmicas en Estados Unidos, Canadá, Europa y a escala internacional. Saber más

Análisis fundamental de ATRI
Puntuación del snowflake
Valoración1/6
Crecimiento futuro0/6
Rendimiento pasado1/6
Salud financiera6/6
Dividendos4/6

Análisis de riesgos

Los beneficios han disminuido un 11.4% al año en los últimos 5 años

Los márgenes de beneficio (6.9%) son inferiores a los del año pasado (15.9%)

El dividendo de 1.91% no está bien cubierto por los beneficios


ATRI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Atrion Corporation

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Atrion
Precios históricos de las acciones
Precio actual de la acciónUS$459.92
Máximo en las últimas 52 semanasUS$503.24
Mínimo de 52 semanasUS$274.98
Beta0.69
Cambio en 1 mes0.62%
Variación en 3 meses-0.88%
Cambio de 1 año-3.11%
Variación en 3 años-35.22%
Variación en 5 años-40.14%
Variación desde la OPV1,790.08%

Noticias y actualizaciones recientes

Recent updates

Artículo de análisis • May 22

There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings

Soft earnings didn't appear to concern Atrion Corporation's ( NASDAQ:ATRI ) shareholders over the last week. We did...
Seeking Alpha • Mar 24

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

Summary Atrion Corporation, a healthcare company focused on fluid delivery products, has experienced a decline in revenue, profits, and cash flows. The drop in sales of fluid delivery products, which account for 42% of overall revenue, has severely impacted the company's top line. Despite the potential for improvement in the future, the stock is currently expensive compared to similar companies, warranting a cautious outlook and a downgrade to a 'sell' rating. Read the full article on Seeking Alpha
Artículo de análisis • Mar 23

Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%

Atrion Corporation ( NASDAQ:ATRI ) shareholders would be excited to see that the share price has had a great month...
Artículo de análisis • Feb 09

Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Artículo de análisis • Jan 04

Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up

Those holding Atrion Corporation ( NASDAQ:ATRI ) shares would be relieved that the share price has rebounded 26% in the...
Artículo de análisis • Sep 14

Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Artículo de análisis • Jul 18

Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Artículo de análisis • Apr 19

Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Artículo de análisis • Oct 18

Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Seeking Alpha • Sep 08

Atrion: Attractively Priced For Exposure To Defensive Healthcare

Summary Artrion Corp. looks well positioned to continue delivering stable, predictable future cash flows. The stock is ideal for those seeking defensive characteristics into equity portfolios. Shares look attractively priced by our estimate of fair value. We rate ATRI a buy on a $632 valuation. Investment Summary Defensive healthcare looks well positioned to catch a bid in the current investment landscape as investors turn to factors of quality and resiliency. Earnings quality and fundamental momentum are paramount to overcome the deep drawdowns experienced across equity markets in FY22. With that, we look to Atrion Corporation (ATRI), a low volatility offering with extensive business history and deep customer networks. ATRI is ideal for investors seeking to add a defensive overlay to equity portfolios, and shares look attractively priced by our estimation. There's also the $2.15 recently declared dividend [+10.3% YoY] that is not discussed here. We rate ATRI a buy $632 price target. Atrion Q2 earnings: in-line with mature growth cycle ATRI came in with a strong set of numbers once again, with top-line growth of 14% printing quarterly revenue of $48.9 million ("mm"). The bolus of upside was driven by a 37% YoY gain in cardiovascular revenues, and 'other' revenues of 14%, offset by weakness in fluid delivery and ophthalmology, as seen in Exhibit 1. Meanwhile, COGS saw a 13% YoY gain due to the higher revenue volumes, whereas inventories lifted by ~690bps YoY. The spike in inventory value was driven by a 13% increase in raw material value, in-line with market trends and the commodity bull run of the past 12 months. This resulted in a gross profit of $20.8mm, up 16.6% YoY on a gross margin of 42.6%. Exhibit 1. The cardiovascular business continues to be the major performer on a sequential basis. Revenue split continues to shift toward a more even distribution towards cardiovascular. Cardiovascular margin is now ~37% of turnover in Q2 FY22. Note: Adapted from ATRI Q2 FY22 10-Q (Image: HB Insights. Data: ATRI) As seen in Exhibit 2, quarterly operating trends have been consistently buoyant for ATRI from FY15-date. Both turnover and operating profit have ticked up from low-points during the pandemic, whereas FCF [net of dividends] has been narrowing from FY20-date. We note the QoQ decline in FCF yield that investors have realized over this time, which, at face value looks to be quite alarming. Exhibit 2. Quarterly operating metrics demonstrate the resiliency on offer, with sales and pre-tax earnings both lifting back above pre-pandemic levels. Noted is the declining FCF yield on tighter FCF conversion, however, as we discuss below, this is coupled with favorable return on investment to justify the case. Note: [All earnings figures in $mm or %]. Quarterly operating measures are plotted against TTM FCF yield to observe effect of invested capital and return on invested capital. Calculations are made from GAAP earnings with no reconciliations. (Image: HB Insights; Data: ATRI SEC Filings) In light of the tightening FCF and FCF yields our findings illustrate that ATRI's return on investment has remained in the double digits across the examination period. Whilst FCF [net of dividends] has narrowed sequentially, ROIC has remained high and curled up since late FY21 on a TTM basis, as seen in Exhibit 3. This tells us the company is amid a strong capital budgeting cycle that has seen it invest more than it made during the period [in Q2 FY22 in particular]. The combination of negative FCF and rising return on investment is a favorable combination that is incredibly attractive in the current climate. Exhibit 3. Despite tightening FCF and realized FCF yields since FY15, ATRI continuously delivers double-digit return on investment that comfortably outpaces the WACC hurdle of 5% by ~2.8 turns. Note: All figures are in $mm or %. Invested capital is calculated with capitalized R&D investment from the income statement. (Image: HB Insights. Data: ATRI SEC filings) Valuation Shares are trading at 32x trailing earnings, ahead of the sector median's 26.6x. The stock is also priced at 4.5x book value, again a step above the sector's 2.2x. We need to understand what we're buying in ATRI. Valuation is a combination of investment, return on investment and earnings by our estimate - what's real, and what's expected.
Artículo de análisis • Aug 27

Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's

The board of Atrion Corporation ( NASDAQ:ATRI ) has announced that it will be paying its dividend of $2.15 on the 30th...
Seeking Alpha • Aug 22

Atrion raises dividend 10.3% to $2.15/share

Atrion (NASDAQ:ATRI) declares $2.15/share quarterly dividend, 10.3% increase from prior dividend of $1.95. Forward yield 1.38% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See ATRI Dividend Scorecard, Yield Chart, & Dividend Growth.
Artículo de análisis • Jul 18

Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Artículo de análisis • Jan 03

Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Artículo de análisis • Nov 18

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation ( NASDAQ:ATRI ) will increase its dividend on the 15th of December to US$1.95. This takes the annual...
Artículo de análisis • Sep 03

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation's ( NASDAQ:ATRI ) dividend will be increasing to US$1.95 on 30th of September. This takes the annual...

Rentabilidad de los accionistas

ATRIUS Medical EquipmentMercado US
7D0.1%4.4%1.1%
1Y-3.1%-17.9%28.7%

Rentabilidad vs. Industria: Los resultados de ATRI fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -17.9% el año pasado.

Rentabilidad vs. Mercado: ATRI obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.

Volatilidad de los precios

Is ATRI's price volatile compared to industry and market?
ATRI volatility
ATRI Average Weekly Movement1.6%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: ATRI no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ATRI ha disminuido de 7% a 2% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
1944712David Battatwww.atrioncorp.com

Atrion Corporation, junto con sus filiales, desarrolla, fabrica y vende productos para aplicaciones de administración de fluidos, cardiovasculares y oftálmicas en Estados Unidos, Canadá, Europa y a escala internacional. Los productos de suministro de fluidos de la empresa incluyen válvulas que llenan, retienen y liberan cantidades controladas de fluidos o gases para su uso en diversas aplicaciones de intubación, intravenosas, de catéter y otras en los campos de la anestesia y la oncología, así como para promover el control de infecciones en entornos hospitalarios y de asistencia sanitaria a domicilio. Sus productos cardiovasculares comprenden el Sistema de Protección Miocárdica, que suministra fluidos y medicamentos y mezcla fármacos críticos, además de controlar la temperatura, la presión y otras variables; válvulas de alivio de vacío para cirugía cardíaca; lazos vasculares de silicona para retraer y ocluir vasos; y dispositivos de inflado para dilatación de catéteres con balón, despliegue de stents y dispensación de fluidos, así como productos para uso en cirugía de bypass cardíaco.

Resumen de fundamentos de Atrion Corporation

¿Cómo se comparan los beneficios e ingresos de Atrion con su capitalización de mercado?
Estadísticas fundamentales de ATRI
Capitalización bursátilUS$809.44m
Beneficios(TTM)US$12.56m
Ingresos (TTM)US$181.60m
64.5x
Ratio precio-beneficio (PE)
4.5x
Ratio precio-ventas (PS)

¿Está ATRI sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ATRI
IngresosUS$181.60m
Coste de los ingresosUS$121.05m
Beneficio brutoUS$60.55m
Otros gastosUS$47.99m
BeneficiosUS$12.56m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)7.13
Margen bruto33.34%
Margen de beneficio neto6.91%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado ATRI a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.9%
Rentabilidad actual por dividendo
123%
Ratio de pagos

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/08/21 09:27
Precio de las acciones al final del día2024/08/21 00:00
Beneficios2024/06/30
Ingresos anuales2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Atrion Corporation está cubierta por 1 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Norbert KalliwodaDr. Kalliwoda Research